+7 (499) 340 10 14

Adverse Effect Detected

During clinical studies of emicizumab (ACE910), a drug for treatment of severe hemophilia, four patients developed side effects. One of them developed thrombosis, the others had a condition leading to deposit of clots in capillaries and small arteries.

However, Roche, the company that developed the drug, is not going to discontinue the development with a large volume of investments. On the contrary, additional studies will be performed to find out the causes of adverse reaction.

Автор: http://labmgmu.ru/

LABMGMU LABMGMU +7 (499) 340 10 14 info@labmgmu.ru 119435, Moscow, Malaya Pirogovskay str. 13-1, floor 4